CTDSPL

Summary

CTDSPL (CTD small phosphatase like, HGNC:16890) is a protein-coding gene on chromosome 3p22.2, encoding CTD small phosphatase-like protein (O15194). Recruited by REST to neuronal genes that contain RE-1 elements, leading to neuronal gene silencing in non-neuronal cells.

Predicted to enable RNA polymerase II CTD heptapeptide repeat phosphatase activity. Predicted to be involved in chromatin remodeling and regulation of transcription by RNA polymerase II. Predicted to act upstream of or within negative regulation of G1/S transition of mitotic cell cycle and negative regulation of protein phosphorylation. Located in extracellular exosome. Biomarker of lung non-small cell carcinoma.

Source: NCBI Gene 10217 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 36 total — 1 pathogenic
• MANE Select transcript: NM_001008392

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16890
Approved symbol	CTDSPL
Name	CTD small phosphatase like
Location	3p22.2
Locus type	gene with protein product
Status	Approved
Aliases	HYA22, SCP3, PSR1, RBSP3
Ensembl gene	ENSG00000144677
Ensembl biotype	protein_coding
OMIM	608592
Entrez	10217

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 7 protein_coding, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000273179, ENST00000310189, ENST00000416688, ENST00000435525, ENST00000436654, ENST00000443503, ENST00000447745, ENST00000486978, ENST00000885349, ENST00000948927

RefSeq mRNA: 2 — MANE Select: NM_001008392 NM_001008392, NM_005808

CCDS: CCDS33734, CCDS33735

Canonical transcript exons

ENST00000273179 — 8 exons

Exon	Start	End
ENSE00001498522	37980742	37984469
ENSE00001908648	37861880	37862278
ENSE00003462368	37971407	37971499
ENSE00003513587	37967826	37967882
ENSE00003551120	37957111	37957143
ENSE00003608535	37947057	37947211
ENSE00003691831	37975709	37975894
ENSE00003692415	37964571	37964672

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 97.80.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.6867 / max 148.7481, expressed in 1661 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
36075	6.9984	1609
36077	2.7934	1244
36076	0.7378	481
36074	0.4663	239
36072	0.3680	171
36073	0.1445	67
36078	0.1138	48
36080	0.0645	15

Top tissues by expression

298 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
metanephric glomerulus	UBERON:0004736	97.80	gold quality
renal glomerulus	UBERON:0000074	97.70	gold quality
nipple	UBERON:0002030	97.02	gold quality
renal medulla	UBERON:0000362	96.81	gold quality
parotid gland	UBERON:0001831	96.60	gold quality
tibia	UBERON:0000979	95.84	gold quality
cardia of stomach	UBERON:0001162	95.56	gold quality
kidney epithelium	UBERON:0004819	95.46	gold quality
secondary oocyte	CL:0000655	95.44	gold quality
pylorus	UBERON:0001166	95.18	gold quality
upper leg skin	UBERON:0004262	95.01	gold quality
upper arm skin	UBERON:0004263	94.22	gold quality
hair follicle	UBERON:0002073	94.14	gold quality
urethra	UBERON:0000057	93.94	gold quality
oocyte	CL:0000023	93.92	gold quality
cortex of kidney	UBERON:0001225	93.79	gold quality
saphenous vein	UBERON:0007318	93.76	gold quality
metanephros	UBERON:0000081	93.62	gold quality
visceral pleura	UBERON:0002401	93.49	gold quality
dorsal root ganglion	UBERON:0000044	93.23	gold quality
kidney	UBERON:0002113	93.17	gold quality
right coronary artery	UBERON:0001625	93.03	gold quality
trachea	UBERON:0003126	93.03	gold quality
adult mammalian kidney	UBERON:0000082	92.92	gold quality
penis	UBERON:0000989	92.79	gold quality
sural nerve	UBERON:0015488	92.74	gold quality
gall bladder	UBERON:0002110	92.73	gold quality
stromal cell of endometrium	CL:0002255	92.43	gold quality
skin of hip	UBERON:0001554	92.09	gold quality
nephron tubule	UBERON:0001231	92.03	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	38.81
E-ANND-3	yes	11.23

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

117 targeting CTDSPL, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-6739-5P	99.80	67.87	2806

Literature-anchored findings (GeneRIF, showing 13)

• analysis of RBSP3/HYA22located in the AP20 region, and evidence for tumor suppressor function (PMID:15051889)
• SCP3 acts as a phosphatase for regulatory phosphorylations in the linker regions of Smad1 and Smad2. (PMID:17085434)
• Frequent alterations of RBSP3 at chromosomal 3p22.3 region in early and late-onset breast carcinoma are reported with reference to clinical and prognostic significance. (PMID:19016758)
• Down-regulation of RBSP3/CTDSPL, NPRL2/G21, RASSF1A, ITGA9, HYAL1 and HYAL2 genes in non-small cell lung cancer (PMID:19140316)
• This is the first report of high frequencies of somatic mutations in RASSF1 and RBSP3 in different cancers suggesting it may underlay the mutator phenotype of cancer. (PMID:19478941)
• In cervical intraepithelial neoplasms and uterine cervical carinoma, RBSP3 is oftne deletd, compared with other genes. (PMID:19885927)
• tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A are downregulated in primary non-small cell lung cancer (PMID:20193080)
• identified RBSP3, a phosphatase-like tumor suppressor, as a bona fide target of miR-100 and validated that RBSP3 was involved in cell differentiation and survival in acute myeloid leukemia (PMID:21643017)
• CTDSPL and Rb directly interact and can be involved in the common mechanism of cell cycle regulation. (PMID:27414789)
• we have presented herein the novel finding that miR-181b contributes to cell cycle progression through depressing the expression of CTDSPL, which in turn activates the downstream effector E2F1 and promotes S-phase entry. (PMID:29382357)
• our data also suggests the importance ofLIMD1 and CDC25A in conjunction with HPV for use as diagnostic and prognostic markers of HNSCC, whereas RBSP3 as a prognostic marker only. (PMID:29672635)
• Tumor suppressor properties of the small C-terminal domain phosphatases in non-small cell lung cancer. (PMID:31774910)
• Hsa-miR-503-5p regulates CTDSPL to accelerate cisplatin resistance and angiogenesis of lung adenocarcinoma cells. (PMID:37341065)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	ctdsplb	ENSDARG00000062116
danio_rerio	ctdspla	ENSDARG00000071673
mus_musculus	Ctdspl	ENSMUSG00000047409
rattus_norvegicus	Ctdspl	ENSRNOG00000046257
drosophila_melanogaster	hzg	FBGN0036556
caenorhabditis_elegans	scpl-1	WBGENE00007054

Paralogs (5): TIMM50 (ENSG00000105197), CTDSPL2 (ENSG00000137770), CTDSP1 (ENSG00000144579), CTDSP2 (ENSG00000175215), CTDNEP1 (ENSG00000175826)

Protein

Protein identifiers

CTD small phosphatase-like protein — O15194 (reviewed: O15194)

Alternative names: Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 3, NIF-like protein, Nuclear LIM interactor-interacting factor 1, Protein YA22, RBSP3, Small C-terminal domain phosphatase 3

All UniProt accessions (5): O15194, F8WED2, H7C2B9, H7C2S4, H7C353

UniProt curated annotations — full annotation on UniProt →

Function. Recruited by REST to neuronal genes that contain RE-1 elements, leading to neuronal gene silencing in non-neuronal cells. Preferentially catalyzes the dephosphorylation of ‘Ser-5’ within the tandem 7 residue repeats in the C-terminal domain (CTD) of the largest RNA polymerase II subunit POLR2A. Negatively regulates RNA polymerase II transcription, possibly by controlling the transition from initiation/capping to processive transcript elongation.

Subunit / interactions. Interacts with REST. Monomer.

Subcellular location. Nucleus.

Tissue specificity. Expression is restricted to non-neuronal tissues.

Cofactor. Binds 1 Mg(2+) ion per monomer.

Isoforms (2)

UniProt ID	Names	Canonical?
O15194-1	1, HYA22B	yes
O15194-2	2, HYA22A

RefSeq proteins (2): NP_001008393, NP_005799 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004274	FCP1_dom	Domain
IPR011948	Dullard_phosphatase	Domain
IPR023214	HAD_sf	Homologous_superfamily
IPR036412	HAD-like_sf	Homologous_superfamily
IPR040078	RNA_Pol_CTD_Phosphatase	Family
IPR050365	TIM50	Family

Pfam: PF03031

Catalyzed reactions (Rhea), 2 shown:

• O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] + phosphate (RHEA:20629)
• O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] + phosphate (RHEA:47004)

UniProt features (36 total): strand 12, helix 9, sequence variant 3, binding site 3, active site 2, site 2, chain 1, domain 1, splice variant 1, turn 1, region of interest 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2HHL	X-RAY DIFFRACTION	2.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O15194-F1	78.64	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (4): 112 (4-aspartylphosphate intermediate); 114 (proton donor); 168 (transition state stabilizer); 206 (transition state stabilizer)

Ligand- & substrate-binding residues (3): 112; 114; 223

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 210 (showing top): GCACCTT_MIR18A_MIR18B, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, AAGCAAT_MIR137, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_CELL_CYCLE_PHASE_TRANSITION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, MODULE_493, BOYLAN_MULTIPLE_MYELOMA_D_DN, GTGCCTT_MIR506, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS, LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP, BOYLAN_MULTIPLE_MYELOMA_D_CLUSTER_DN, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE, BLALOCK_ALZHEIMERS_DISEASE_UP, GTGTTGA_MIR505

GO Biological Process (2): negative regulation of G1/S transition of mitotic cell cycle (GO:2000134), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (7): RNA polymerase II CTD heptapeptide repeat phosphatase activity (GO:0008420), metal ion binding (GO:0046872), phosphoprotein phosphatase activity (GO:0004721), protein serine/threonine phosphatase activity (GO:0004722), protein binding (GO:0005515), hydrolase activity (GO:0016787), phosphatase activity (GO:0016791)

GO Cellular Component (2): nucleus (GO:0005634), extracellular exosome (GO:0070062)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
G1/S transition of mitotic cell cycle	1
negative regulation of mitotic cell cycle phase transition	1
negative regulation of cell cycle G1/S phase transition	1
regulation of G1/S transition of mitotic cell cycle	1
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
protein serine/threonine phosphatase activity	1
RNA polymerase II CTD heptapeptide repeat modifying activity	1
cation binding	1
phosphatase activity	1
catalytic activity, acting on a protein	1
phosphoprotein phosphatase activity	1
binding	1
catalytic activity	1
phosphoric ester hydrolase activity	1
intracellular membrane-bounded organelle	1
extracellular vesicle	1

Protein interactions and networks

STRING

1209 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CTDSPL	CTDP1	Q9Y5B0	750
CTDSPL	REST	Q13127	732
CTDSPL	GTF2F1	P35269	583
CTDSPL	WDR35	Q9P2L0	507
CTDSPL	ITGA9	Q13797	493
CTDSPL	ELMO3	Q96BJ8	479
CTDSPL	IFT122	Q9HBG6	479
CTDSPL	KDM5C	P41229	451
CTDSPL	ELMO2	Q96JJ3	448
CTDSPL	LRRC3B	Q96PB8	448
CTDSPL	GULP1	Q9UBP9	448
CTDSPL	NIFK	Q9BYG3	447
CTDSPL	KCNN4	O15554	439
CTDSPL	VILL	O15195	435
CTDSPL	LIMD1	Q9UGP4	432

IntAct

21 interactions, top by confidence:

A	B	Type	Score
CDCA3	CTDSPL	psi-mi:“MI:0914”(association)	0.670
CTDSP1	CTDSPL	psi-mi:“MI:0914”(association)	0.640
CTDSP1	CTDSP2	psi-mi:“MI:0914”(association)	0.530
SMAD1	CTDSPL	psi-mi:“MI:0915”(physical association)	0.400
SMAD2	CTDSPL	psi-mi:“MI:0915”(physical association)	0.400
CTDSPL	FGFR2	psi-mi:“MI:0915”(physical association)	0.370
MBP	CTDSPL	psi-mi:“MI:0914”(association)	0.350
CTDSPL	TBC1D4	psi-mi:“MI:0914”(association)	0.350
MAGEA8	METTL15	psi-mi:“MI:0914”(association)	0.350
KCNE3	PIK3R2	psi-mi:“MI:0914”(association)	0.350
CTDSP1	XPO1	psi-mi:“MI:0914”(association)	0.350
CTDSP2	CTDSPL	psi-mi:“MI:0914”(association)	0.350
CTDSPL	ESYT2	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (102): CTDSPL (Affinity Capture-MS), CTDSPL (Affinity Capture-MS), CDCA3 (Affinity Capture-MS), TBC1D4 (Affinity Capture-MS), ARVCF (Proximity Label-MS), CADM1 (Proximity Label-MS), RFTN1 (Proximity Label-MS), PACS1 (Proximity Label-MS), DAB2IP (Proximity Label-MS), ARHGAP39 (Proximity Label-MS), CD44 (Proximity Label-MS), ABCC1 (Proximity Label-MS), ATP2B4 (Proximity Label-MS), NOTCH1 (Proximity Label-MS), PVRL2 (Proximity Label-MS)

ESM2 similar proteins: A5A3E0, C4B7M5, C4B7M6, E1B328, F4JCB2, F4K487, O15194, O80443, P0C6E7, P0CAP5, P0CG38, P0CG39, P0DKG6, P0DKH5, P14721, Q00IB6, Q5RM09, Q683D5, Q69TF4, Q6L3Y2, Q6S8J3, Q70SU8, Q84JE8, Q84WJ0, Q84WP3, Q8GWJ4, Q8GYE8, Q8GZ84, Q8LRK8, Q8RXK2, Q944B6, Q94A51, Q9C5P0, Q9C5Q9, Q9C7F1, Q9FHE8, Q9FJX8, Q9FJX9, Q9FKF0, Q9FV02

Diamond homologs: A4QNX6, M9PFN0, O13636, O14595, O15194, O59718, O95476, P0CN66, P0CN67, P38757, P58465, P58466, Q02776, Q05D32, Q07800, Q07949, Q08BB5, Q09695, Q1RMV9, Q20432, Q28HW9, Q29I63, Q3B7T6, Q3KQB6, Q3TP92, Q3ZCQ8, Q4I099, Q4PEW9, Q4WI16, Q54GB2, Q59W44, Q5B4P0, Q5F3Z7, Q5RAJ8, Q5S7T7, Q5U395, Q5U3T3, Q5XIK8, Q61C05, Q66KM5

SIGNOR signaling

13 interactions.

A	Effect	B	Mechanism
CTDSPL	“up-regulates activity”	RB1	dephosphorylation
CTDSPL	“up-regulates activity”	SMAD3	dephosphorylation
CTDSPL	“down-regulates activity”	SMAD2	dephosphorylation
CTDSPL	“down-regulates activity”	SMAD1	dephosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

36 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	29
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
665052	NC_000003.12:g.(?37452365)(38950372_?)del	Pathogenic

SpliceAI

2432 predictions. Top by Δscore:

Variant	Effect	Δscore
3:37862278:GGTG:G	donor_loss	1.0000
3:37862280:T:G	donor_loss	1.0000
3:37947055:A:AG	acceptor_gain	1.0000
3:37947056:G:GC	acceptor_gain	1.0000
3:37947209:AAG:A	donor_loss	1.0000
3:37947211:GGTC:G	donor_loss	1.0000
3:37947212:G:GC	donor_loss	1.0000
3:37947213:T:G	donor_loss	1.0000
3:37964668:TTAAG:T	donor_loss	1.0000
3:37964669:TAAG:T	donor_loss	1.0000
3:37964670:AAG:A	donor_loss	1.0000
3:37964671:AG:A	donor_loss	1.0000
3:37964672:GG:G	donor_loss	1.0000
3:37964673:GT:G	donor_loss	1.0000
3:37964674:T:A	donor_loss	1.0000
3:37967824:A:AG	acceptor_gain	1.0000
3:37967825:G:GG	acceptor_gain	1.0000
3:37967878:ATCAG:A	donor_loss	1.0000
3:37967879:TCAGG:T	donor_loss	1.0000
3:37967880:CAG:C	donor_loss	1.0000
3:37967881:AGGT:A	donor_loss	1.0000
3:37967882:GG:G	donor_loss	1.0000
3:37967884:T:A	donor_loss	1.0000
3:37971402:TGCA:T	acceptor_loss	1.0000
3:37971403:GCA:G	acceptor_loss	1.0000
3:37971404:CA:C	acceptor_loss	1.0000
3:37971405:A:AG	acceptor_gain	1.0000
3:37971405:AGGT:A	acceptor_gain	1.0000
3:37971406:G:GG	acceptor_gain	1.0000
3:37971406:GGT:G	acceptor_gain	1.0000

AlphaMissense

1834 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:37964632:T:A	V110D	1.000
3:37964635:T:A	I111N	1.000
3:37964637:G:C	D112H	1.000
3:37964638:A:C	D112A	1.000
3:37964638:A:G	D112G	1.000
3:37964638:A:T	D112V	1.000
3:37964639:T:A	D112E	1.000
3:37964639:T:G	D112E	1.000
3:37964641:T:C	L113S	1.000
3:37964643:G:A	D114N	1.000
3:37964643:G:C	D114H	1.000
3:37964643:G:T	D114Y	1.000
3:37964644:A:C	D114A	1.000
3:37964644:A:G	D114G	1.000
3:37964644:A:T	D114V	1.000
3:37964645:T:A	D114E	1.000
3:37964645:T:G	D114E	1.000
3:37964647:A:C	E115A	1.000
3:37964647:A:T	E115V	1.000
3:37964648:A:C	E115D	1.000
3:37964648:A:T	E115D	1.000
3:37964649:A:C	T116P	1.000
3:37964650:C:G	T116R	1.000
3:37964650:C:T	T116I	1.000
3:37964653:T:C	L117S	1.000
3:37964653:T:G	L117W	1.000
3:37964656:T:A	V118E	1.000
3:37964658:C:G	H119D	1.000
3:37964660:C:A	H119Q	1.000
3:37964660:C:G	H119Q	1.000

dbSNP variants (sampled 300 via entrez): RS1000006521 (3:37962850 T>G), RS1000035363 (3:37970346 T>G), RS1000046690 (3:37877377 T>C), RS1000122915 (3:37915125 A>G), RS1000132073 (3:37949257 A>C), RS1000151499 (3:37869266 ATTTC>A), RS1000155460 (3:37914696 C>G), RS1000155905 (3:37913696 A>C), RS1000156432 (3:37883642 A>C,G), RS1000206732 (3:37984483 T>C), RS1000246504 (3:37934544 G>A,T), RS1000281302 (3:37977101 A>G), RS1000336170 (3:37882056 C>A,G), RS1000347096 (3:37863374 G>C), RS1000380792 (3:37920436 C>T)

Disease associations

OMIM: gene MIM:608592 | disease phenotypes: MIM:189800, MIM:601144

GenCC curated gene-disease

Mondo (2): preeclampsia (MONDO:0005081), Brugada syndrome (MONDO:0015263)

Orphanet (2): Preeclampsia (Orphanet:275555), Brugada syndrome (Orphanet:130)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST000095_5	Prostate cancer	2.000000e-06
GCST90002383_363	Hematocrit	7.000000e-24
GCST90002384_203	Hemoglobin	3.000000e-22
GCST90002388_191	Lymphocyte count	4.000000e-11
GCST90002393_399	Monocyte count	1.000000e-10
GCST90002403_139	Red blood cell count	1.000000e-20
GCST90020028_794	Hip circumference adjusted for BMI	3.000000e-08

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004348	hematocrit
EFO:0004509	hemoglobin measurement
EFO:0004587	lymphocyte count
EFO:0005091	monocyte count
EFO:0004305	erythrocyte count
EFO:0008039	BMI-adjusted hip circumference

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D053840	Brugada Syndrome	C14.280.067.322; C14.280.123.250; C16.320.100
D011225	Pre-Eclampsia	C12.050.703.395.249

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

59 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, increases methylation	5
sodium arsenite	affects methylation, decreases expression, affects cotreatment, increases abundance	3
bisphenol F	increases expression, affects cotreatment, decreases expression	2
bisphenol A	affects expression, decreases methylation	2
Air Pollutants	decreases expression, increases abundance	2
Arsenic	affects methylation, affects cotreatment, decreases expression, increases abundance	2
Benzo(a)pyrene	decreases expression, decreases methylation	2
Nickel	decreases expression	2
Tobacco Smoke Pollution	decreases expression	2
Aflatoxin B1	increases methylation	2
FR900359	decreases phosphorylation	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
trichostatin A	increases expression	1
beta-lapachone	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
butyraldehyde	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
potassium chromate(VI)	decreases expression	1
aflatoxin B2	increases methylation	1
coumarin	increases phosphorylation	1
triacsin C	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, decreases expression	1
beta-methylcholine	affects expression	1
paricalcitol	affects cotreatment, decreases expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	increases expression	1
abrine	decreases expression	1

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1PJ	Abcam HeLa CTDSPL KO	Cancer cell line	Female
CVCL_SK04	HAP1 CTDSPL (-) 1	Cancer cell line	Male
CVCL_SK05	HAP1 CTDSPL (-) 2	Cancer cell line	Male
CVCL_SK06	HAP1 CTDSPL (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00117546	PHASE4	UNKNOWN	Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
NCT00567957	PHASE4	UNKNOWN	Remifentanil for General Anesthesia in Preeclamptics
NCT01030627	PHASE4	COMPLETED	Treatment Approaches to Preeclampsia
NCT01352234	PHASE4	COMPLETED	Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
NCT01361425	PHASE4	UNKNOWN	Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)
NCT01729468	PHASE4	COMPLETED	Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers
NCT01761916	PHASE4	COMPLETED	Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure
NCT01912677	PHASE4	COMPLETED	Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
NCT02025426	PHASE4	TERMINATED	Phenylephrine Versus Ephedrine in Pre-eclampsia
NCT02091401	PHASE4	COMPLETED	A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen
NCT02163655	PHASE4	COMPLETED	Diuretics for Postpartum High Blood Pressure in Preeclampsia
NCT02338687	PHASE4	COMPLETED	Low Dose Calcium to Prevent Preeclampsia
NCT02396030	PHASE4	TERMINATED	Different Schemes of Magnesium Sulfate for Preeclampsia
NCT02531490	PHASE4	UNKNOWN	Early Vascular Adjustments During Hypertensive Pregnancy
NCT02699827	PHASE4	COMPLETED	Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia
NCT02835339	PHASE4	COMPLETED	Magnesium Sulfate in Obese Preeclamptics
NCT02891174	PHASE4	COMPLETED	The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy
NCT02911701	PHASE4	COMPLETED	Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
NCT03171480	PHASE4	COMPLETED	Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
NCT03233880	PHASE4	UNKNOWN	Impact of Antichlamydial Treatment on the Rate of Preeclampsia
NCT03237000	PHASE4	UNKNOWN	Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients
NCT03506724	PHASE4	COMPLETED	Response to Anti-hypertensives in Pregnant and Postpartum Patients
NCT03674606	PHASE4	COMPLETED	Trial of Early Screening Test for Pre-eclampsia and Growth Restriction
NCT03735433	PHASE4	TERMINATED	The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
NCT03824119	PHASE4	UNKNOWN	Postpartum NSAIDS and Maternal Hypertension
NCT04051567	PHASE4	UNKNOWN	Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies
NCT04077853	PHASE4	COMPLETED	Progesterone in Expectantly Managed Early-onset Preeclampsia
NCT04158830	PHASE4	WITHDRAWN	Aspirin (ASA) Therapy and Preeclampsia Prevention
NCT04424693	PHASE4	UNKNOWN	Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36
NCT04631627	PHASE4	UNKNOWN	Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
NCT04656665	PHASE4	UNKNOWN	The Effectiveness of Aspirin on Preventing Pre-eclampsia
NCT04797949	PHASE4	WITHDRAWN	Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia
NCT04908982	PHASE4	UNKNOWN	Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension
NCT05221164	PHASE4	UNKNOWN	162 mg of Aspirin for Prevention of Preeclampsia
NCT05294952	PHASE4	UNKNOWN	co Ihibtory Receptor in Preeclampsia
NCT05514847	PHASE4	ACTIVE_NOT_RECRUITING	Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
NCT05586373	PHASE4	COMPLETED	Ibuprofen vs Dipyrone After C-section in Preeclampsia
NCT06069102	PHASE4	COMPLETED	Optimal Blood Pressure Treatment Thresholds Postpartum
NCT06107335	PHASE4	NOT_YET_RECRUITING	Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia
NCT06281665	PHASE4	RECRUITING	Treatment With Aspirin After Preeclampsia: TAP Trial